IVAX Corporation has entered into an exclusive agreement with Eli Lilly and Company to develop and market the AMPA receptor antagonist, talampanel, worldwide. Phase II clinical trials with talampanel in patients with severe epilepsy not responsive to other drugs have shown positive results and phase III trials in epilepsy will be done to confirm and Read more about IVAX Acquires Drug In Advanced Clinical Development[…]